Trial Profile
A Prospective, Multicenter, Double-randomized, Double-blind, 2-parallel Groups, Phase 3 Study to Compare as First Line Therapy Efficacy and Safety of Masitinib in Combination With Gemcitabine, to Gemcitabine in Combination With Placebo, in the Treatment of Patients With Non Resectable Locally Advanced or Metastatic Pancreatic Cancer
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 18 Jan 2023
Price :
$35
*
At a glance
- Drugs Masitinib (Primary) ; Fluorouracil; Folinic acid; Gemcitabine; Irinotecan
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Registrational; Therapeutic Use
- Sponsors AB Science
- 10 Jun 2021 Results of a subgroup analysis assessing the presence of pain in pancreatic cancer to identify patients whose disease is driven in part by a pro-tumoral immune response published in the AB Science Media Release.
- 10 Jun 2021 According to an AB Science media release, results from this trial were published in the Journal of Clinical Oncology.
- 10 Jun 2021 According to an AB Science media release, results from this trial were presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting.